Pre-treatment with recombinant TIMP-1 of mice with experimental colitis reduced the mucosal pathology [60] while splenocytes from pretreated mice produced less TNF-α and more IL-10 than untreated mice following stimulation with anti-CD3 [60]. This evidence concerns the gene TNF and colitis.